Wedge Industrial Co Ltd (000534) Fair Value & Analysis
Healthcare · CN · Market cap 14.0B CNY (≈ $2.1B) · ISIN CNE0000004T4
What is Wedge Industrial Co Ltd really worth?
Below-average quality, and trading another 288% above our fair value of ¥6.43.
Strengths
Risks
Fair value as of: Aug 26, 2026
From 9 valuation models · updated 10 days ago
Share price −6.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥8.04). The favourable scenario is already priced in.
- Weak quality (42/100) and above fair value at the same time, the margin of safety is missing on both counts.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 26, 2026.
How to read this chart
60‑month range ¥8.66 – ¥47.65 · fair‑value band ¥4.82 – ¥8.04 · the ¥24.92 price screens above the ¥6.43 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 26, 2026.
Analysis
Wedge Industrial Co Ltd (000534) currently trades at ¥24.92, while our model-based Fair Value estimate is ¥6.43, implying the stock looks roughly 287.6% overvalued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bull case: the Multiples group reads highest at a median of ¥6.43 per share, and 0 of the 9 models we run sit above the ¥24.92 price. Bear case: the Asset-Based group reads lowest at ¥1.79, and 9 of the 9 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Wedge Industrial Co Ltd generated revenue of 1.3B CNY at a net margin of 15.3%. Revenue grew 7.4% year over year. It earns a return on equity of 9.7%. Net debt stands at 1.1B CNY. Fundamentals as of Aug 26, 2026
Our scenario range runs from ¥4.82 (bear case) to ¥8.04 (bull case); at ¥24.92, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 49% below its 52-week high and 94% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −74%, 000534 screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2024 figures, and about 12 months have passed since. In that time the company retained roughly ¥0.4000 per share, which is 6.2 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 9 models by family
Widest divergence: Multiples (¥6.43) versus Asset-Based (¥1.79). Highest evidence: Residual Income (71).
Notify me when 000534 reaches fair value
Put 000534 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 26, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 39 · Market factors (momentum, volatility) 46
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Wedge Industrial Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of micro-ecological live bacteria products, superalloys, and related products in China.
Full company description
Wedge Industrial Co.,Ltd., together with its subsidiaries, engages in the research and development, production, and sale of micro-ecological live bacteria products, superalloys, and related products in China. The company offers micro-ecological preparations, such as bifidobacterium lactobacillus triple live bacteria tablets under the Golden Bifidobacterium brand; vaginal lactobacillus live capsules under the Dingjunsheng brand; dual-span microecological live bacteria drugs under the Jinshuangqi brand; and vaginal microecological live bacteria drug for use in the treatment of gynecological infections under the Dingjunsheng brand. It also provides probiotic products, health food products, probiotic dietary supplements, probiotic hand creams, and other probiotic health products under the Sanlian Probiotics, Bacteria powder, and Today's Bacteria brands. In addition, the company is involved in the research, development, and manufacture of high-temperature alloy materials and core components, including precision casting blades, high temperature alloy powder discs, high temperature master alloys and their alloy powders, and nickel-based high-temperature master alloys. Wedge Industrial Co.,Ltd. was formerly known as Guangdong Wanze Industrial Co., Ltd. and changed its name to Wedge Industrial Co., Ltd. in May 2013. The company was founded in 1992 and is based in Shantou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
Wedge Industrial Co Ltd reported revenue of 1.1B CNY in FY2024 versus 553M CNY in FY2020, a compound +18.2%/yr. Reported net income was 193M CNY in FY2024, compounding +25.9%/yr from FY2020.
of which total revenue +3.2 % · buybacks/dilution +0.1 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
000534 screens 288% overvalued. Compare with Merck KGaA →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Wedge Industrial Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Wedge Industrial Co Ltd (000534) overvalued or undervalued?
What is the fair value of 000534?
What is the quality score of 000534?
What is the revenue of Wedge Industrial Co Ltd (000534)?
What is the net profit margin of 000534?
Watch Wedge Industrial Co Ltd in the live analysis
One click puts Wedge Industrial Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.